Market Closed -
Nasdaq
02:00:00 04/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1.7
USD
|
+3.03%
|
|
+17.24%
|
+8.97%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
309
|
633.5
|
198.8
|
233.9
|
-
|
-
|
Enterprise Value (EV)
1 |
309
|
633.5
|
198.8
|
233.9
|
233.9
|
233.9
|
P/E ratio
|
-2.42
x
|
-13.6
x
|
-4.73
x
|
-3.51
x
|
-3.38
x
|
-10.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
20.9
x
|
2.32
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
20.9
x
|
2.32
x
|
EV / EBITDA
|
-3.8
x
|
-15.5
x
|
-4
x
|
-3.46
x
|
-3.09
x
|
-3.25
x
|
EV / FCF
|
-1,43,36,714
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
97,472
|
1,25,938
|
1,27,455
|
1,37,589
|
-
|
-
|
Reference price
2 |
3.170
|
5.030
|
1.560
|
1.700
|
1.700
|
1.700
|
Announcement Date
|
18/03/22
|
15/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
11.19
|
100.9
|
EBITDA
1 |
-
|
-81.32
|
-40.87
|
-49.66
|
-67.56
|
-75.61
|
-72.06
|
EBIT
1 |
-
|
-81.88
|
-41.66
|
-50.36
|
-68.3
|
-81.32
|
-32.83
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-726.84%
|
-32.54%
|
Earnings before Tax (EBT)
1 |
-29.47
|
-82.18
|
-39.22
|
-42.49
|
-64.88
|
-78.54
|
-29.99
|
Net income
1 |
-29.5
|
-82.18
|
-39.22
|
-42.49
|
-66.34
|
-79.35
|
-27.21
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-709.23%
|
-26.96%
|
EPS
2 |
-
|
-1.310
|
-0.3700
|
-0.3300
|
-0.4843
|
-0.5029
|
-0.1614
|
Free Cash Flow
|
-
|
-21.55
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/03/21
|
18/03/22
|
15/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-12.88
|
-7.017
|
-8.767
|
-12.4
|
-12.69
|
-9.517
|
-13.16
|
-11.76
|
-15.23
|
-15.7
|
-16.24
|
-17.58
|
-18.03
|
-17.03
|
EBIT
1 |
-5.854
|
-13
|
-7.182
|
-8.987
|
-12.6
|
-12.89
|
-9.711
|
-13.34
|
-11.93
|
-15.39
|
-15.51
|
-16.5
|
-17.28
|
-18.19
|
-17.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-5.975
|
-12.99
|
-7.162
|
-8.494
|
-11.98
|
-11.59
|
-7.837
|
-11.28
|
-9.964
|
-13.42
|
-14.51
|
-15.52
|
-16.66
|
-17.62
|
-17.2
|
Net income
1 |
-5.975
|
-12.98
|
-7.162
|
-8.494
|
-11.98
|
-11.59
|
-7.837
|
-11.28
|
-9.964
|
-13.42
|
-14.78
|
-15.98
|
-17.07
|
-18.02
|
-17.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1000
|
-0.0500
|
-0.0700
|
-0.0800
|
-0.1200
|
-0.1000
|
-0.0600
|
-0.0900
|
-0.0800
|
-0.1100
|
-0.1129
|
-0.1200
|
-0.1243
|
-0.1229
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
18/03/22
|
09/05/22
|
01/08/22
|
09/11/22
|
15/03/23
|
04/05/23
|
03/08/23
|
09/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-21.6
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.89
|
0.21
|
-
|
0.03
|
0.03
|
0.03
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
0.27%
|
0.03%
|
Announcement Date
|
05/03/21
|
18/03/22
|
15/03/23
|
21/03/24
|
-
|
-
|
-
|
Average target price
9.167
USD Spread / Average Target +439.22% Consensus |
1st Jan change
|
Capi.
|
---|
| +8.97% | 234M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|